CN103108658B - 抗体制剂 - Google Patents

抗体制剂 Download PDF

Info

Publication number
CN103108658B
CN103108658B CN201180042125.5A CN201180042125A CN103108658B CN 103108658 B CN103108658 B CN 103108658B CN 201180042125 A CN201180042125 A CN 201180042125A CN 103108658 B CN103108658 B CN 103108658B
Authority
CN
China
Prior art keywords
antibody
aminoacid sequence
sequence seq
antibody fragment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180042125.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108658A (zh
Inventor
M·N·季米特洛娃
N·莫迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN103108658A publication Critical patent/CN103108658A/zh
Application granted granted Critical
Publication of CN103108658B publication Critical patent/CN103108658B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201180042125.5A 2010-07-02 2011-07-01 抗体制剂 Expired - Fee Related CN103108658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36120910P 2010-07-02 2010-07-02
US61/361,209 2010-07-02
PCT/US2011/042838 WO2012003470A2 (en) 2010-07-02 2011-07-01 Antibody formulations

Publications (2)

Publication Number Publication Date
CN103108658A CN103108658A (zh) 2013-05-15
CN103108658B true CN103108658B (zh) 2015-08-19

Family

ID=45402685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180042125.5A Expired - Fee Related CN103108658B (zh) 2010-07-02 2011-07-01 抗体制剂

Country Status (9)

Country Link
US (1) US8754195B2 (enExample)
EP (1) EP2588141A4 (enExample)
JP (2) JP2013531679A (enExample)
CN (1) CN103108658B (enExample)
AU (2) AU2011274363A1 (enExample)
BR (1) BR112012033457A2 (enExample)
CA (1) CA2803998A1 (enExample)
SG (1) SG186421A1 (enExample)
WO (1) WO2012003470A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
JP6157611B2 (ja) * 2012-06-21 2017-07-05 ユセベ ファルマ ソシエテ アノニム 医薬製剤
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
BR112016006397B1 (pt) * 2013-09-27 2024-01-16 Genentech, Inc Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição
JP6799904B2 (ja) * 2014-07-31 2020-12-16 キユーピー株式会社 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
WO2017095848A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
AU2016369557B2 (en) 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
EP4271412A4 (en) * 2020-12-30 2024-12-04 Ammax Bio, Inc Extended local release of antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191490A (zh) * 1995-07-27 1998-08-26 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010013A1 (en) 1989-02-09 1990-09-07 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1992013867A1 (en) 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
US5444151A (en) 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2004050850A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2560046A1 (en) 2004-03-16 2005-09-22 Dnavec Research Inc. Methods for suppressing tumor proliferation
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
PL2100618T3 (pl) * 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
EP2029163A4 (en) * 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191490A (zh) * 1995-07-27 1998-08-26 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies

Also Published As

Publication number Publication date
WO2012003470A2 (en) 2012-01-05
US8754195B2 (en) 2014-06-17
CN103108658A (zh) 2013-05-15
SG186421A1 (en) 2013-01-30
JP2013531679A (ja) 2013-08-08
AU2016201291A1 (en) 2016-03-17
CA2803998A1 (en) 2012-01-05
EP2588141A4 (en) 2014-12-03
JP2016026164A (ja) 2016-02-12
EP2588141A2 (en) 2013-05-08
US20120009199A1 (en) 2012-01-12
BR112012033457A2 (pt) 2017-04-04
AU2011274363A1 (en) 2013-01-24
WO2012003470A3 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
CN103108658B (zh) 抗体制剂
US10689451B2 (en) Anti-BAFFR antibody therapeutic formulations
US20100260766A1 (en) Stable antibody formulations
US20250195649A1 (en) High Concentration Bispecific Antibody Formulations
CA3080137A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
US12358981B2 (en) Anti-connexin antibody formulations
US20220288208A1 (en) Cetuximab-ir700 conjugate compositions
US20240034813A1 (en) High Concentration Bispecific Antibody Formulations
US12180284B2 (en) Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
TWI844697B (zh) 用於穩定液體蛋白質調配物之組合物及方法
JP2024538140A (ja) 抗ｏｘ４０モノクローナル抗体を含む医薬製剤
WO2024098180A1 (en) Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
WO2024231860A1 (en) Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
HK40060084A (en) Composition and methods for stabilizing liquid protein formulations
WO2025056748A1 (en) Antibody-drug conjugate
HK1203146B (en) Antibody formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150819

Termination date: 20170701

CF01 Termination of patent right due to non-payment of annual fee